Trial Profile
A Phase 2 Study of Check Point Inhibitor, Durvalumab (Medi4736) for Bacillus Calmette-Guérin (BCG) Refractory Urothelial Carcinoma in Situ (CIS) of the Bladder
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 01 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary)
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- 28 Jul 2023 Results published in the Clinical Cancer Research
- 16 May 2022 Results presented at the 117th Annual Meeting of the American Urological Association
- 10 Nov 2020 Status changed from recruiting to active, no longer recruiting.